SCHEMBL9040995

SCHEMBL9040995

Cc1cc(C(=O)O)cc(S(C)(=O)=O)c1C

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PKM P14618 1/20 0.55
TPMT P51580 1/20 0.43
ALDH1A1 P00352 4/20 0.43
MEN1 O00255 1/20 0.42
KMT2A Q03164 1/20 0.42
DNMT3B Q9UBC3 1/20 0.41
SMN1; SMN2 Q16637 2/20 0.41
TTR P02766 1/20 0.40
LCK P06239 1/20 0.39
FYN P06241 1/20 0.39
HCAR1 Q9BXC0 1/20 0.38
GPR35 Q9HC97 1/20 0.38
CDC25B P30305 1/20 0.38
CPT2 P23786 1/20 0.38
CPT1A P50416 1/20 0.38
CPT1B Q92523 1/20 0.38
NSD2 O96028 1/20 0.37
ESR1 P03372 1/20 0.37
POLB P06746 1/20 0.37
APEX1 P27695 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9041076 0.83 PKM (0.54) PKMTPMTALDH1A1MEN1KMT2A
SCHEMBL30219263 0.83 SMN1; SMN2 (0.43) PKMSMN1; SMN2L3MBTL1
SCHEMBL31401501 0.81 HDAC1 (0.42) PKMTPMTALDH1A1SMN1; SMN2TTR
SCHEMBL22400558 0.81 TTR (0.47) PKMTPMTTTRLCKFYN
SCHEMBL31401376 0.81 TTR (0.47) PKMTPMTKMT2ASMN1; SMN2TTR
SCHEMBL31401435 0.81 PKM (0.42) PKMTPMTKMT2ASMN1; SMN2TTR
SCHEMBL23714796 0.80 PKM (0.51) PKMTPMTALDH1A1MEN1KMT2A
SCHEMBL9436642 0.80 VCAM1 (0.47) PKMALDH1A1SMN1; SMN2POLBTDP1
SCHEMBL1572119 0.79 TPMT (0.59) PKMTPMTALDH1A1MEN1KMT2A
SCHEMBL2590708 0.77 L3MBTL1 (0.53) PKMALDH1A1MEN1KMT2ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4739682-A1 1,6-NAPHTHRIDINE COMPOUNDS AS SMARCA2 INHIBITORS USEFUL FOR THE TREATMENT OF SMARCA4 DEFICIENT CANCERS Janssen Pharmaceutica NV (BE) 2026-05-13 EP disclosed
WO-2025008058-A1 1,6-NAPHTHRIDINE COMPOUNDS AS SMARCA2 INHIBITORS USEFUL FOR THE TREATMENT OF SMARCA4 DEFICIENT CANCERS JANSSEN PHARMACEUTICA NV (BE) 2025-01-09 WO disclosed
EP-0556674-B1 3,5-substituted benzoylguanidines with antiarrhythmic activity and cell proliferation inhibiting activity HOECHST AG (DE) 1996-06-19 EP disclosed
US-5373024-A 3,5-Substituted benzoylguanidines, process for their preparation, their use as a medicament of diagnostic and medicament containing them HOECHST AKTIENGESELLSCHAFT (DE) 1994-12-13 US disclosed
EP-0556674-A1 3,5-substituted benzoylguanidines with antiarrhythmic activity and cell proliferation inhibiting activity HOECHST AKTIENGESELLSCHAFT (DE) 1993-08-25 EP disclosed